Acetoacetic Acid

Acetoacetic Acid

SCHEMBL9682963

CC(=O)CC(=O)O.CCCC(O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
CHRM1 P11229 1/20 0.41
AKR1A1 P14550 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KDM4E B2RXH2 1/20 0.38
KDM6B O15054 1/20 0.38
KDM5C P41229 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
HDAC8 Q9BY41 2/20 0.37
HDAC7 Q8WUI4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetoacetic Acid SCHEMBL2381598 1.00 HDAC1 (0.41) HDAC1HDAC2TDP1CHRM1AKR1A1
Acetoacetic Acid SCHEMBL867995 0.89 ALOX15 (0.41) HDAC1HDAC2TDP1CHRM1AKR1A1
Malonic Acid SCHEMBL28697215 0.88 LDHA (0.47) HDAC1HDAC2TDP1CHRM1AKR1A1
Acetoacetic Acid SCHEMBL9681644 0.87 GPR84 (0.42) GPR84FFAR1FFAR4TSHRALDH1A1
Acetoacetic Acid SCHEMBL9680475 0.87 GPR84 (0.42) GPR84FFAR1FFAR4TSHRALDH1A1
Acetoacetic Acid SCHEMBL1627295 0.85 GPR84 (0.50) TDP1GPR84FFAR1FFAR4TSHR
Acetoacetic Acid SCHEMBL3909150 0.83 KDM4E (0.42) HDAC1HDAC2TDP1KDM4EKDM6B
Acetoacetic Acid SCHEMBL3627073 0.83 KDM4E (0.42) HDAC1HDAC2TDP1KDM4EKDM6B
Acetic Acid SCHEMBL11353075 0.83 CHRM1 (0.50) HDAC1HDAC2TDP1CHRM1AKR1A1
Acetic Acid SCHEMBL11353114 0.83 CHRM1 (0.50) HDAC1HDAC2TDP1CHRM1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285348-A1 COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE UNIVERSITY OF SOUTH FLORIDA 2023-09-14 US claimed
US-20200397736-A1 COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE UNIVERSITY OF SOUTH FLORIDA 2020-12-24 US claimed
EP-3723511-A1 COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE University of South Florida (US) 2020-10-21 EP claimed
WO-2019118624-A1 COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE UNIVERSITY OF SOUTH FLORIDA (US) 2019-06-20 WO claimed
CN-108042516-A Application of R, S-1,3- the butanediol acetoacetate diester in prevention or treatment decompression medicine is prepared 中国人民解放军第二军医大学 2018-05-18 CN claimed
US-20170266147-A1 METHODS OF INCREASING LATENCY OF ANESTHETIC INDUCTION USING KETONE SUPPLEMENTATION NAVY, SECRETARY OF THE UNITED STATES OF AMERICA 2017-09-21 US claimed
US-11974973-B2 Ketone supplements-evoked effect on absence epilepsy by co-administration of uridine UNIVERSITY OF SOUTH FLORIDA (US) 2024-05-07 US disclosed
EP-3788109-B1 METHOD FOR PROVIDING SUBSTRATE COATED WITH A CURED DAMPING COATING AND COATED SUBSTRATE SO PROVIDED DOW GLOBAL TECHNOLOGIES LLC (US) 2023-06-07 EP disclosed
US-11643569-B2 Method for providing substrate coated with a cured damping coating and coated substrate so provided DOW GLOBAL TECHNOLOGIES LLC (US) 2023-05-09 US disclosed
CN-112004894-B Method for providing a substrate coated with a cured damping coating and the provided coated substrate 陶氏环球技术有限责任公司 2022-09-27 CN disclosed
US-20220218635-A1 KETONE SUPPLEMENTS-EVOKED EFFECT ON ABSENCE EPILEPSY BY CO-ADMINISTRATION OF URIDINE EOTVOS LORAND UNIVERSITY (HU) 2022-07-14 US disclosed
US-20210338613-A1 FORMULATIONS AND METHODS FOR TRANSDERMAL ADMINISTRATION OF KETONES DYVE BIOSCIENCES, INC. (US) 2021-11-04 US disclosed
US-20210290581-A1 NEUROREGENERATION IMPROVED BY KETONE UNIVERSITY OF SOUTH FLORIDA 2021-09-23 US disclosed
WO-2015156865-A1 METHODS OF SUSTAINING DIETARY KETOSIS AND ITS EFFECTS ON LIPID PROFILE UNIVERSITY OF SOUTH FLORIDA (US) 2015-10-15 WO disclosed
US-20140072654-A1 CANCER WITH METABOLIC THERAPY AND HYPERBARIC OXYGEN SAVIND, INC. (US) 2014-03-13 US disclosed
US-20140073693-A1 USE OF KETONE ESTERS FOR PREVENTION OF CNS OXYGEN TOXICITY SAVIND, INC. (US) 2014-03-13 US disclosed
WO-2012154837-A2 THE USE OF KETONE ESTERS FOR PREVENTION OF CNS OXYGEN TOXICITY UNIVERSITY OF SOUTH FLORIDA (US) 2012-11-15 WO disclosed
US-5126373-A Ester or diester of 1,3-butanediol or 1,3-pentanediol; side effect reduction BRUNENGRABER HENRI (US) 1992-06-30 US disclosed
US-4997976-A Use of 1,3-butanediol acetoacetate in parenteral oral nutrition BRUNENGRABER HENRI (CA) 1991-03-05 US disclosed
EP-0318357-A2 1,3-Butanediol acetoacetate and its use in parenteral and oral nutrition Brunengraber, Henri (CA) 1989-05-31 EP disclosed